Community-Acquired Pneumonia (CAP) is an acute infection of the pulmonary parenchyma accompanied by symptoms of acute illness and abnormal chest findings.
It is a lower respiratory tract infection acquired in the community within 24 hours to <2 weeks or occurring ≤48 hours of hospital admission in patients who do not meet the criteria for healthcare-associated pneumonia.
It occurs at the highest rates in the very young and the very old.
Potentially life-threatening especially in older adults and those with comorbid disease.
Lung ultrasound proves to be a useful tool for screening community-acquired pneumonia in the emergency department (ED), with a recent study showing that its use brings down diagnostic uncertainty from 73 percent to 14 percent.
Ultrasound appears to provide a fast, reliable, and sensitive point-of-care tool for detecting interstitial lung disease among HIV-positive patients, according to a study. However, ultrasound falls short of differentiating between different disease aetiologies.
The fixed-dosing omadacycline strategy demonstrates consistent safety and efficacy in patients with community-acquired bacterial pneumonia (CABP), regardless of body mass index (BMI), according to a phase III trial.
In the treatment of patients with community-acquired bacterial pneumonia (CABP), omadacycline is as effective as moxifloxacin at inducing response in patients with Pneumonia Patient Outcomes Research Team (PORT) risk class III and IV, according to data from the phase III OPTIC* trial.
Adding empirical anti-methicillin-resistant Staphylococcus aureus (MRSA) therapy to standard antibiotic regimens in patients hospitalized for pneumonia is associated with an elevated risk of 30-day all-cause mortality, a recent retrospective study found.